ArticlePediatric research2026
Linear growth and metabolic outcomes of growth hormone treatment in childhood-onset craniopharyngioma: the OUTSPREAD study.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowth hormone (GH) deficiency is common following craniopharyngioma resection. This study aimed to compare growth status and metabolic parameters before and after GH treatment for patients with craniopharyngioma.
methodsThis retrospective study included 134 patients with multicenter study for Ideal Outcomes of Pediatric Rare Endocrine and Metabolic Diseases in Korea (OUTSPREAD study), who received GH treatment for ≥1 year. Data on growth and metabolic parameters before and after GH treatment (at 1, 2, and 3 years, and at the end of treatment) were collected.
resultsThe mean age at diagnosis was 7.6 years, with GH treatment initiated at 9.4 years and concluded at 15.7 years. Before GH treatment, height and weight were below average, while body mass index (BMI) was above average. Following GH treatment, height and weight significantly increased while BMI decreased. Analysis using a sex-, age- and steroid dose- adjusted linear mixed model showed significantly decreased aspartate aminotransferase, alanine aminotransferase and total cholesterol levels after treatment. Random glucose levels increased slightly but remained within the normal range, and glycosylated hemoglobin levels remained stable.
conclusionThis is the first longitudinal report showing the positive effects of GH treatment for craniopharyngioma in Korean patients. IMPACT: After surgery for craniopharyngioma, GH treatement is essential for patients with GH deficiency. In this first multicenter Korean cohort evaluating long-term growth and metabolic outcomes, GH treatment significantly improved height, weight, and BMI SDS. Hepatic indices (AST/ALT) and lipid parameters (total cholesterol) decreased during treatment. Random glucose increased slightly but remained within the normal range, and HbA1c showed no significant change. These findings support GH treatment as a key component of long-term management with benefits beyond linear growth.
Identifiers
42115721What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.